Olaparib Patent Expiration
Olaparib is Used for treating various types of cancers, including breast, ovarian, pancreatic, and metastatic prostate cancer, in patients with specific gene mutations undergoing specific chemotherapy regimens. It was first introduced by Astrazeneca Pharmaceuticals Lp
Olaparib Patents
Given below is the list of patents protecting Olaparib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lynparza | US11633396 | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one | Oct 07, 2029 | Astrazeneca |
| Lynparza | US11970530 | Methods of treating homologous recombination deficient cancer | Oct 25, 2041 | Astrazeneca |
| Lynparza | US11975001 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Oct 07, 2029 | Astrazeneca |
| Lynparza | US7151102 | Phthalazinone derivatives |
Apr 29, 2022
(Expired) | Astrazeneca |
| Lynparza | US7449464 | Phthalazinone derivatives | Oct 11, 2024 | Astrazeneca |
| Lynparza | US7449464 | Phthalazinone derivatives | Sep 08, 2027 | Astrazeneca |
| Lynparza | US7981889 | Phthalazinone derivatives | Oct 11, 2024 | Astrazeneca |
| Lynparza | US8071579 | DNA damage repair inhibitors for the treatment of cancer | Aug 12, 2027 | Astrazeneca |
| Lynparza | US8143241 | DNA damage repair inhibitors for treatment of cancer | Aug 12, 2027 | Astrazeneca |
| Lynparza | US8247416 | Phthalazinone derivative | Sep 24, 2028 | Astrazeneca |
| Lynparza | US8475842 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Dec 31, 2029 | Astrazeneca |
| Lynparza | US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer | Aug 04, 2031 | Astrazeneca |
| Lynparza | US8912187 | Phthalazinone derivatives |
Mar 12, 2024
(Expired) | Astrazeneca |
| Lynparza | US9169235 | Phthalazinone derivatives |
Mar 12, 2024
(Expired) | Astrazeneca |
| Lynparza | US9566276 | Phthalazinone derivatives |
Mar 12, 2024
(Expired) | Astrazeneca |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳